Table 2 Analysis of the impact of adalimumab compared with disease-modifying antirheumatic drug (DMARD) treatment on work outcomes
Adalimumab vs DMARD-treated patients (95% CI)
Additional duration worked (years)*
    All patients0.17 (0.11 to 0.22)
    Patients working at baseline0.61 (0.42 to 0.79)
Hazard ratio for stopping work†
    All patients0.36 (0.30 to 0.42)
    Patients working at baseline0.36 (0.15 to 0.85)
  • *Duration worked for patients receiving adalimumab versus DMARDs from multivariate ordinary least-square regression controlling for percentage working at baseline (for analysis of all patients only) and baseline age, erythrocyte sedimentation rate, C-reactive protein concentration, number of swollen and tender joints, 28-joint Disease Activity Score, and joint pain, patient-rated global and physician-rated global assessment visual analogue scale scores.

  • †Hazard ratio for patients receiving adalimumab compared with DMARDs from proportional hazards regression controlling for time to event (stopping work), duration of study enrolment, percentage working at baseline (for analysis of all patients only), and baseline age, erythrocyte sedimentation rate, C-reactive protein, number of swollen and tender joints, 28-joint Disease Activity Score, and joint pain, patient-rated global and physician-rated global assessment visual analogue scale scores.